Bioactivation of herbal constituents: Simple alerts in the complex system

Expert Opinion on Drug Metabolism and Toxicology

Volumn 7, Issue 8, 2011, Pages 989-1007

  Fang, Zhong Ze ^a,b   Zhang, Yan Yan ^a   Wang, Xiu Li ^a   Cao, Yun Feng ^a   Huo, Hong ^a   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

Author keywords

bioactivation; herbal medicines; herbal toxicity; herbdrug interactions

Indexed keywords

ALLICIN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BERGAMOTTIN; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; DAURICINE; DRUG METABOLIZING ENZYME; ESTRAGOLE; EVODIAMINE; FLAVONOID; FUROSEMIDE; GLABRIDIN; HERBACEOUS AGENT; KAVA; LIMONIN; MENTHOFURAN; METHOXSALEN; METHYLEUGENOL; NOSCAPINE; PYRROLIZIDINE ALKALOID; RESVERATROL; RUTAECARPINE; SAFROLE; SILIBININ; UNINDEXED DRUG; WARFARIN;

ADVERSE OUTCOME; ANTINEOPLASTIC ACTIVITY; ANXIETY DISORDER; BASIL; CARDIOVASCULAR DISEASE; DRUG DETOXIFICATION; DRUG GLUCURONIDATION; DRUG METABOLISM; ENZYME INHIBITION; GERMANDER; GRAPEFRUIT JUICE; HERBAL DRUG BIOACTIVATION; HERBAL MEDICINE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSOMNIA; LIVER CARCINOGENESIS; LIVER CIRRHOSIS; LIVER DISEASE; LIVER METABOLISM; LIVER TOXICITY; LUNG TOXICITY; MAXIMUM PLASMA CONCENTRATION; MEDLINE; NEPHROTOXICITY; NONHUMAN; PARAPSORIASIS; PROTEIN MODIFICATION; PROTEIN POLYMORPHISM; PSORIASIS; REVIEW; T CELL LYMPHOMA; VITILIGO;

ANIMALS; HERB-DRUG INTERACTIONS; HERBAL MEDICINE; HUMANS; METABOLIC DETOXICATION, DRUG; PLANT PREPARATIONS; PLANTS, MEDICINAL;

EID: 79960526327     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2011.586335     Document Type: Review

References (140)

1. Williamson E. Drug interactions between herbal and prescription medicines. Drug Saf 2003;26:1075-92 (Pubitemid 38021390)
2. Winslow L, Kroll D. Herbs as medicines. Arch Intern Med 1998;158:2192-9 (Pubitemid 28512493)
3. Woolf AD, Watson WA, Smolinske S, et al. The severity of toxic reactions to Ephedra: Comparisons to other botanical products and national trends from 1993-2002. Clin Toxicol 2003;43:347-55 (Pubitemid 41428767)
4. De Smet PAGM. Health risks of herbal remedies. Clin Pharmacol Ther 2004;76:1-17
5. Zhou SF, Zhou ZW, Li CG, et al. Identification of drugs that interact with herbs in drug development. Drug Discov Today 2007;12:664-73
6. Guengerich FP. Cytochrome P450s and other enzymes in drug metabolism and toxicity. AAPS J 2006;8:E101-11
7. Ma S, Subramanian R. Detecting and characterizing reactive metabolites by liquid chromatography/tandem mass spectrometry. J Mass Spectrom 2006;41:1121-39 (Pubitemid 44454166)
8. Zhou SF, Koh HL, Gao YH, et al. Herbal bioactivation: the good, the bad and the ugly. Life Sci 2004;74:935-68
9. Zhou SF, Xue CC, Yu XQ, et al. Metabolic activation of herbal and dietary constituents and its clinical and toxicological implications: an update. Curr Drug Metab 2007;8:526-53 (Pubitemid 47209094)
10. Kalgutkar AS, Gardner I, Obach RS, et al. A comprehensive listing of bioactivation pathways of organic functional groups. Curr Drug Metab 2005;6:161-225 (Pubitemid 40753853)
11. Smith KS, Smith PL, Heady TN, et al. In vitro metabolism of tolcapone to reactive intermediates: relevance to tolcapone liver toxicity. Chem Res Toxicol 2003;16:123-8
12. Chauret N, Gauthier A, Martin J, et al. In vitro comparison of cytochrome P450-mediated metabolic activities in human, dog, cat and horse. Drug Metab Dispos 1997;25:1130-6
13. Vanherweghem JL, Depierreux M, Tielemans C, et al. Rapidly progressive interstitial renal fibrosis in young women: association with slimming regimen including Chinese herbs. Lancet 1993;341:387-91 (Pubitemid 23048140)
14. Solez K, Daugirdes J, Gregory MC, et al. Is ?Chinese Herbs Nephropathy? a prejudical term? Am J Kidney Dis 2001;38:1141-2
15. Stiborova M, Frei E, Wiessler M, et al. Human enzymes involved in the metabolic activation of carcinogenic aristolochic acids: evidence for reductive activation by cytochromes P450 1A1 and 1A2. Chem Res Toxicol 2001;14:1128-37 (Pubitemid 32800169)
16. Stiborova M, Frei E, Sopko B, et al. Carcinogenic aristolochic acids upon activation by DT-diaphorase from adducts found in DNA of patients with Chinese herbs nephropathy. Carcinogenesis 2002;23:617-25 (Pubitemid 34498500)
17. Pfau W, Schmeiser HH, Wiessler M. Aristolochic acid binds covalently to the exocyclic amino group of purine nucleotides in DNA. Carcinogenesis 1990;11:313-19 (Pubitemid 20072170)
18. Schmeiser HH, Bieler CA, Wiessler M, et al. Detection of DNA adducts formed by aristolochic acid in renal tissue from patients with Chinese herbs nephropathy. Cancer Res 1996;56:2025-8 (Pubitemid 26119902)
19. Schmeiser HH, Janssen JW, Lyons J, et al. Aristolochic acid activates ras genes in rat tumors at deoxyadenosine residues. Cancer Res 1990;50:5464-9 (Pubitemid 20303005)
20. Schmeiser HH, Scherf HR, Wiessler M, et al. Activating mutations at codon 61 of the c-Ha-ras gene in thin-tissue sections of tumors induced by aristolochic acid in rats and mice. Cancer Res 1991;59:139-43
21. Arlt VM, Stiborova M, Schmeiser HH. Aristolochic acid as a probable human cancer hazard in herbal remedies: a review. Mutagenesis 2002;17:265-77 (Pubitemid 34814645)
22. Murray M. Mechanisms of inhibitory and regulatory effects of methylenedioxyphenyl compounds on cytochrome P450-dependent drug oxidation. Curr Drug Metab 2000;1:67-84
23. Amacher DE, Fasulo LM, Charuel C, et al. In vitro toxicity of zamifenacin (UK-76654) and metabolites in primary hepatocyte cultures. Xenobiotica 1998;28:895-908 (Pubitemid 28446365)
24. Zhao SX, Dalvie DK, Kelly JM, et al. NADPH-dependent covalent binding of [H-3] paroxetine to human liver microsomes and S-9 fractions: identification of an electrophilic quinone metabolite of paroxetine. Chem Res Toxicol 2007;20(11):1649-57 (Pubitemid 350275610)
25. Wislocki PG, Miller EC, Killer JA, et al. Carcinogenic and mutagenic activities of safrole, 1′-hydroxysafrole, and some known or possible metabolites. Cancer Res 1977;37:1883-91 (Pubitemid 8095207)
26. Jeurissen SMF, Bogaards JJP, Awad HM, et al. Human cytochrome P450 enzyme specificity for bioactivation of safrole to the proximate carcinogen 1′-hydroxysafrole. Chem Res Toxicol 2004;17:1245-50 (Pubitemid 39265880)
27. Ueng YF, Hsieh CH, Don MJ, et al. Identification of the main human cytochrome P450 enzymes involved in safrole 1′hydroxylation. Chem Res Toxicol 2004;17:1151-6
28. Bolton JL, Acay NM, Vukomanovic V. Evidence that 4-Allyl-o-quinones spontaneously rearrange to their more electrophilic quinone methides: potential bioactivation mechanism for the hepatocarcinogen safrole. Chem Res Toxicol 1994;7:443-50 (Pubitemid 24150107)
29. Randerath K, Putman KL, Randerath E. Flavor constituents in cola drinks induce hepatic DNA adducts in adult and fetal mice. Biochem Biophys Res Commun 1993;192:61-8 (Pubitemid 23205268)
30. Beyer J, Ehlers D, Maurer HH. Abuse of nutmeg (Myristica fragrans Houtt.): studies on the metabolism and the toxicologic detection of its ingredients elemicin, myristicin and safrole in rat and human urine using gas chromatography/mass spectrometry. Ther Drug Monit 2006;28:568-75 (Pubitemid 44181492)
31. Empey DW, Laitinen LA, Young GA, et al. Comparison of the antitussive effects of codeine phosphate 20 mg, dextromethorphan 30 mg and noscapine 30 mg using citric acid-induced cough in normal subjects. Eur J Clin Pharmacol 1979;16:393-7 (Pubitemid 10173750)
32. Ye KQ, Ke Y, Keshava N, et al. Opium alkaloid noscapine is an antitumor agent that arrests metaphase and induces apoptosis in dividing cells. Proc Natl Acad Sci USA 1998;95:1601-6 (Pubitemid 28103439)
33. Fang ZZ, Zhang YY, Ge GB, et al. Time-dependent inhibition (TDI) of CYP3A4 and CYP2C9 by noscapine potentially explains clinical noscapine-warfarin interaction. Br J Clin Pharmacol 2010;69:193-9
34. Rosenborg S, Stenberg M, Otto S, et al. Clinically significant CYP2C inhibition by noscapine but not by Glucosamine. Clin Pharmacol Ther 2010;88:343-6
35. Witte S, Loew D, Gaus W. Meta-analysis of the efficacy of the acetonic kava-kava extract WS1490 in patients with non-psychotic anxiety disorders. Phytother Res 2005;19:183-8 (Pubitemid 40827638)
36. Clouatre DL. Kava kava: examining new reports of toxicology. Toxicol Lett 2004;150:85-96 (Pubitemid 38447238)
37. Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatotoxicity. Phytomedicine 2003;10:440-6 (Pubitemid 36745169)
38. Johnson BM, Qiu SX, Zhang S, et al. Identification of novel electrophilic metabolites of Piper methysticum Forst. (Kava). Chem Res Toxicol 2003;16:733-40 (Pubitemid 36736604)
39. Mathews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extracts and kavalactones. Drug Metab Dispos 2002;30:1153-7 (Pubitemid 35265819)
40. Fang ZZ, Zhang YY, Ge GB, et al. Identification of cytochrome P450 (CYP) isoforms involved in the metabolism of corynoline and assessment of its herb-drug interactions. Phytother Res 2011;25:256-63
41. Iwata H, Tezuka Y, Kadota S, et al. Identification and characterization of potent CYP3A4 inhibitors in Schisandra Fruit extract. Drug Metab Dispos 2004;32:1351-8 (Pubitemid 39564554)
42. Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic- intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos 2003;31:1391-7 (Pubitemid 37310329)
43. Wirth PJ, Bettis CJ, Nelson WL. Microsomal metabolism of furosemide evidence for nature of reactive intermediate involved in covalent binding. Mol Pharmacol 1976;12:759-68
44. Kouzi SA, McMurtry RJ, Nelson SD. Hepatotoxicity of germander (Teucrium chamaedrys L.) and one of its constituent neoclerodane diterpenes teucrin A in the mouse. Chem Res Toxicol 1994;7:850-6 (Pubitemid 24370245)
45. Laliberte L, Villeneuve JP. Hepatitis after the use of germander, a herbal remedy. CMAJ 1996;154:1689-92 (Pubitemid 26178864)
46. De Berardinis V, Moulis C, Maurice M, et al. Human microsomal epoxide hydrolase is the target of germander-induced autoantibodies on the surface of human hepatocytes. Mol Pharmacol 2000;58:542-51
47. Lekehal M, Pessayre D, Lereau JM, et al. Hepatotoxicity of the herbal medicine germander: Metabolic activation of its furano diterpenoids by cytochrome P450 3A depletes cytoskeleton-associated protein thiols and forms plasma membrane blebs in rat hepatocytes. Hepatology 1996;24:212-18 (Pubitemid 26249436)
48. Druckova A, Marnett LJ. Characterization of the amino acid adducts of the enedial derivative of teucrin A. Chem Res Toxicol 2006;19:1330-40 (Pubitemid 44607319)
49. He K, Iyer KR, Hayes RN, et al. Inactivation of cytochrome P450 3A4 by bergamottin, a component of grapefruit juice. Chem Res Toxicol 1998;11:252-9 (Pubitemid 28194348)
50. Lim HK, Duczak N Jr, Brougham L, et al. Automated screening with confirmation of mechanism-based inactivation of CYP3A4, CYP2C9, CYP2C19, CYP2D6, and CYP1A2 in pooled human liver microsomes. Drug Metab Dispos 2005;33:1211-19 (Pubitemid 41043765)
51. Bumpus NN, Sridar C, Kent UM, et al. The naturally occurring cytochrome P450 (P450) 2B6 K262R mutant of P4502B6 exhibits alterations in substrate metabolism and inactivation. Drug Metab Dispos 2005;33:795-802 (Pubitemid 40686633)
52. Lin HL, Kent UM, Hollenberg PF. The grapefruit juice effect is not limited to cytochrome P450 (P450) 3A4: evidence for bergamottin-dependent inactivation, heme destruction, and covalent binding to protein in P450s 2B6 and 3A5. J Pharmacol Exp Ther 2005;313:154-64 (Pubitemid 40411339)
53. Kent UM, Lin HL, Noon KR, et al. Metabolism of bergamottin by cytochromes P450 2B6 and 3A5. J Pharmacol Exp Ther 2006;318:992-1005 (Pubitemid 44268304)
54. Koenigs LL, Peter RM, Thompson SJ, et al. Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 1997;25:1407-15 (Pubitemid 28010927)
55. Koenigs LL, Trager WF. Mechanism-based inactivation of cytochrome P450 2B1 by 8-Methoxypsoralen and several other furanocoumarins. Biochemistry 1998;37:13184-93 (Pubitemid 28449562)
56. Koenigs LL, Trager WF. Mechanism-based inactivation of P450 2A6 by Furanocoumarins. Biochemistry 1998;37:10047-61 (Pubitemid 28366359)
57. Iwata H, Tezuka Y, Kadota S, et al. Mechanism-based inactivation of human liver microsomal CYP3A4 by rutaecarpine and limonin from Evodia fruit extract. Drug Metab Pharmacokinet 2005;20:34-45
58. Khojasteh-Bakht SC, Chen W, Koenigs LL, et al. Metabolism of (R)-(+)-pulegone and (R)-(+)- menthofuran by human liver cytochrome P450s: evidence for formation of a furan epoxide. Drug Metab Dispos 1999;27:574-80 (Pubitemid 29214468)
59. Thomassen D, Knebel N, Slattery JT, et al. Reactive intermediates in the oxidation of menthofuran by cytochromes P450. Chem Res Toxicol 1992;5:123-30
60. Slack JA, Fordhutchinson AW. Determination of a urinary epoxide metabolite of alclofenac in man. Drug Metab Dispos 1980;8:84-6 (Pubitemid 10122802)
61. Slack JA, Fordhutchinson AW, Richold M, et al. Some biochemical and pharmacological properties of an epoxide metabolite of alclofenac. Chem Biol Interact 1981;34:95-107 (Pubitemid 11138539)
62. Jeurissen SMF, Punt A, Boersma MG, et al. Human cytochrome P450 enzyme specificity for the bioactivation of estragole and related alkenylbenzenes. Chem Res Toxicol 2007;20:798-806 (Pubitemid 46953687)
63. Boberg EW, Miller EC, Miller JA, et al. Strong evidence from studies with brachymorphic mice and pentachlorophenol that 1′-sulfooxysafrole is the major ultimate electrophilic and carcinogenic metabolite of 1′- hydroxysafrole in mouce liver. Cancer Res 1983;43:5163-73 (Pubitemid 14227494)
64. Jeurissen SMF, Bogaards JJP, Boersma MG, et al. Human cytochrome P450 enzymes of importance for the bioactivation of methyleugenol to the proximate carcinogen 1′-hydroxymethleugenol. Chem Res Toxicol 2006;19:111-16 (Pubitemid 43185468)
65. Gardner I, Wakazono H, Bergin P, et al. Cytochrome P450 mediated bioactivation of methylglyoxal to 1′-hydroxymethyleugenol in Fischer 344 rat and human liver microsomes. Carcinogenesis 1997;18:1775-83 (Pubitemid 28134685)
66. Brady JF, Ishizaki H, Fukuto JM, et al. Inhibition of Cytochrome P450 2E1 by Diallyl Sulfide and its metabolites. Chem Res Toxicol 1991;4:642-7
67. Jin L, Baillie TA. Metabolism of the chemoprotective agent diallyl sulfide to glutathione conjugates in rats. Chem Res Toxicol 1997;10:318-27 (Pubitemid 27137143)
68. Premdas PD, Bowers RJ, Forkert PG. Inactivation of hepatic CYP2E1 by an epoxide of diallyl sulfone. J Pharmacol Exp Ther 2000;293:1112-20 (Pubitemid 30417883)
69. Notley LM, de Wolf CJF, Wunsch RM, et al. Bioactivation of Tamoxifen by recombinant human cytochrome P450 enzymes. Chem Res Toxicol 2002;15:614-22 (Pubitemid 34535116)
70. Kassahun K, Pearson PG, Tang W, et al. Studies on the metabolism of troglitazone to reactive intermediates in vitro and in vivo. Evidence for novel biotransformation pathways involving quinone methide formation and thiazolidinedione ring scission. Chem Res Toxicol 2001;14:62-70 (Pubitemid 32064376)
71. Lai WG, Zahid N, Uetrecht JP. Metabolism of trimethoprim to a reactive iminoquinone methide by activated human neutrophils and hepatic microsomes. J Pharmacol Exp Ther 1999;291:292-9 (Pubitemid 29451602)
72. Du ZH, Liu HG, Chai CY, et al. Anti-inflammatory effect of dauricine. Zhongguo Yao Li Xue Bao 1986;7:419-22
73. Wang Y, Zhong D, Chen X, et al. Identification of quinone methide metabolites of dauricine in human liver microsomes and in rat bile. Chem Res Toxicol 2009;22:824-34
74. Jin H, Dai J, Chen X, et al. Pulmonary toxicity and metabolic activation of dauricine in CD-1 Mice. J Pharmacol Exp Ther 2010;332:738-46
75. Orallo F, Alvarez E, Camina M, et al. The possible implication of trans-resveratrol in the cardioprotective effects of Long-Term moderate wine consumption. Mol Pharmacol 2002;61:294-302 (Pubitemid 34112803)
76. Gusman J, Malonne H, Atassi G. A reappraisal of the potential chemopreventive and chemotherapeutic properties of resveratrol. Carcinogenesis 2001;22:1111-17 (Pubitemid 32737324)
77. Chan WK, Nguyen LT, Miller VP, et al. Mechanism-based inactivation of human cytochrome P450 3A4 by grapefruit juice and red wine. Life Sci 1998;62:135-42
78. Chan WK, Delucchi AB. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4. Life Sci 2000;67:3103-12
79. Chun YJ, Ryu SY, Jeong TC, et al. Mechanism-based inhibition of human cytochrome P450 1A1 by Rhapontigenin. Drug Metab Dispos 2001;29:389-93 (Pubitemid 32275551)
80. Hollman PCH, Katan MB. Absorption, metabolism and health effects of dietary flavonoids in man. Biomed Pharmacother 1997;51:305-10 (Pubitemid 27423753)
81. Sun DX, Lu CJ, Fang ZZ, et al. Reversible inhibition of three important human liver cytochrome P450 enzymes by tiliroside. Phytother Res 2010;24:1670-5
82. Jurado J, Alejandre-Duran E, Alonso-Moraga A, et al. Study on the mutagenic activity of 13 bioflavonoids with the Salmonella Ara test. Mutagenesis 1991;6:289-95
83. Awrd HM, Boersma MG, Boeren S, et al. Quenching of quercetin quinone/quinone methides by different thiolate scavengers: stability and reversibility of conjugate formation. Chem Res Toxicol 2003;16:822-31 (Pubitemid 36898996)
84. Harwood M, Danielewska-Nikiel B, Borzelleca JF, et al. A critical review of the data related to the safety of quercetin and lack of evidence of genotoxic/carcinogenic properties. Food Chem Toxicol 2007;45:2179-205 (Pubitemid 47451573)
85. Kent UM, Aviram M, Rosenblat M, et al. The licorice root derived isoflavan glabridin inhibits the activities of human cytochrome P450s 3A4, 2B6 and 2C9. Drug Metab Dispos 2002;30:709-15 (Pubitemid 34579106)
86. Sridar C, Goosen TC, Kent UM, et al. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos 2004;32:587-94 (Pubitemid 38668150)
87. Madden S, Maggs JL, Park BK. Bioactivation of carbamazepine in the rat in vivo-evidence for the formation of reactive arene oxides. Drug Metab Dispos 1996;24:469-79 (Pubitemid 26119942)
88. Zhuo XL, Gu J, Zhang QY, et al. Biotransformation of coumarin by rodent and human cytochromes P450: metabolic basis of tissue-selective toxicity in olfactory mucosa of rats and mice. J Pharmacol Exp Ther 1999;288:463-71 (Pubitemid 29119652)
89. Born SL, Caudill D, Fliter KL, et al. Identification of the cytochromes P450 that catalyze coumarin 3,4-epoxidation and 3-hydroxylation. Drug Metab Dispos 2002;30:483-7 (Pubitemid 34456966)
90. Born SL, Rodriguez PA, Eddy CL, et al. Synthesis and reactivity of coumarin 3,4-epoxide. Drug Metab Dispos 1997;25:1318-23 (Pubitemid 27490678)
91. Felter SP, Vassallo JD, Carlton BD, et al. A safety assessment of coumarin taking into account species-specificity of toxicokinetics. Food Chem Toxicol 2006;44:462-75 (Pubitemid 43375122)
92. Lake BG. Coumarin metabolism, toxicity and carcinogenicity: relevance for human risk assessment. Food Chem Toxicol 1999;37:423-53 (Pubitemid 29335767)
93. Zhuo XL, Zhao WP, Zheng JN, et al. Bioactivation of coumarin in rat olfactory mucosal microsomes: detection of protein covalent binding and identification of reactive intermediates through analysis of glutathione adducts. Chem Biol Interact 2009;181:227-35
94. Ju C, Uetrecht JP. Oxidation of a metabolite of indomethacin to reactive intermediates by activated neutrophils, hypochlorous acid, and the myeloperoxidase system. Drug Metab Dispos 1998;26:676-80 (Pubitemid 28345851)
95. Roeder E. Medicinal plants in Europe containing pyrrolizidine alkaloids. Pharmazie 1995;50:83-98
96. Roeder E. Medicinal plants in China containing pyrrolizidine alkaloids. Pharmazie 2000;55:711-26
97. Stegelmeier BL, Edgar JA, Colegate SM, et al. Pyrrolizidine alkaloid plants, metabolism and toxicity. J Nat Toxins 1999;8:95-116 (Pubitemid 29125815)
98. Arzt J, Mount ME. Hepatotoxicity associated with pyrrolizidine alkaloid (Crotalaria spp) ingestion in a house on Easter Island. Vet Hum Toxicol 1999;41:96-9 (Pubitemid 29156117)
99. Bah M, Bye R, Pereda-Miranda R. Hepatotoxic pyrrolizidine alkaloids in the Mexican medicinal plant Packera candidissima (Asteraceae: Senecioneae). J Ethnopharmacol 1994;43:19-30 (Pubitemid 24186506)
100. Fu PP, Xia Q, Lin G, et al. Pyrrolizidine alkaloids-genotoxicity, metabolism enzymes, metabolic activation, and mechanisms. Drug Metab Rev 2004;36:1-55 (Pubitemid 38387834)
101. Willett KL, Roth RA, Walker L. Workshop overview: hepatotoxicity assessment for botanical dietary supplements. Toxicol Sci 2004;79:4-9 (Pubitemid 38660241)
102. Jeurissen SMF, Claassen FW, Havlik J, et al. Development of an on-line high performance liquid chromatography detection system for human cytochrome P450 1A2 inhibitors in extracts of natural products. J Chromatogr A 2007;1141:81-9 (Pubitemid 46053952)
103. Jeurissen SMF, Punt A, Delatour T, et al. Basil extract inhibits the sulfotransferase mediated formation of DNA adducts of the procarcinogen 1′-hydroxyestragole by rat and human liver S9 homogenates and in HepG2 human hepatoma cells. Food Chem Toxicol 2008;46:2296-302
104. Alhusainy W, Paini A, Punt A, et al. Identification of nevadensin as an important herb-based constituent inhibiting estragole bioactivation and physiology-based biokinetic modeling of its possible in vivo effect. Toxicol Appl Pharmacol 2010;245:179-90
105. Zhang YY, Yang L. Deoxyschizandrin could attenuate cytochrome P450 3A4-mediated bioactivation of gomisin A in human liver microsomes. Drug Metab Rev 2010;42:140-1
106. Dueker SR, Lame MW, Morin D, et al. Guinea pig and rat hepatic microsomal metabolism of monocrotaline. Drug Metab Dispos 1992;20:275-80
107. Williams DE, Reed RL, Kedzierski B, et al. Bioactivation and detoxification of the pyrrolizidine alkaloid senecionine by cytochrome P450 enzymes in rat liver. Drug Metab Dispos 1989;17:387-92 (Pubitemid 19206579)
108. Williams DE, Reed RL, Kedzierski B, et al. The role of flavin-containing monooxygenase in the N-oxidation of the pyrrolizidine alkaloid senecionine. Drug Metab Dispos 1989;17:380-6 (Pubitemid 19206578)
109. Guenthner TM, Luo G. Investigation of the role of the 2′,3′-epoxidation pathway in the bioactivation and genotoxicity of dietary allylbenzene analogs. Toxicology 2001;160:47-58 (Pubitemid 32200463)
110. Iyer LV, Ho MN, Shinn WM, et al. Glucuronidation of 1′- hydroxyestragole (1′-HE) by human UDP-glucuronosyltransferases UGT2B7 and UGT1A9. Toxicol Sci 2003;73:36-43 (Pubitemid 36609083)
111. Punt A, Paini A, Boersma MG, et al. Use of physiologically based biokinetic (PBBK) modeling to study estragole bioactivation and detoxification in humans as compared with male rats. Toxicol Sci 2009;110:255-69
112. Moon YJ, Wang X, Morris ME. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol Vitro 2006;20:187-210 (Pubitemid 43087702)
113. Kim SK, Moon A. Effect of Glycyrrhiza glabra roots and glycyrrhizin on the glucuronidation in rats. Planta Med 1997;63:115-19 (Pubitemid 27196076)
114. Andrade RJ, Robles M, Ulzurrun E, et al. Drug-induced liver injury: insights from genetic studies. Pharmacogenomics 2009;10:1467-87
115. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present and future. Trends Pharmacol Sci 2004;25:193-200 (Pubitemid 38519910)
116. Tanaka E. Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 1999;24:339-46 (Pubitemid 29520783)
117. Verbeeck RK. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur J Clin Pharmacol 2008;64:1147-61
118. Punt A, Jeurissen SM, Boersma MG, et al. Evaluation of human interindividual variation in bioactivation of estragole using physiologically based biokinetic modeling. Toxicol Sci 2010;113:337-48
119. Rietjens IMCM, Punt A, Schilter B, et al. In silico methods for physiologically based biokinetic models describing bioactivation and detoxification of coumarin and estragole: implications for risk assessment. Mol Nutr Food Res 2010;54:195-207
120. Streetman DS, Bertino JS Jr, Nafziger AN. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000;10:187-216 (Pubitemid 30242736)
121. Martignoni M, Groothuis GMM, de Kanter R. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol 2006;2:875-94 (Pubitemid 44911538)
122. Ma XC, Ning J, Ge GB, et al. Comparative metabolism of cinobufagin in liver microsomes from mouse, rat, dog, minipig, monkey and human. Drug Metab Dispos 2011;published online 4 January 2011, doi: 10.1124/dmd.110.036830
123. Liang SC, Ge GB, Liu HX, et al. Determination of propofol UDP-glucurosyltrnasferase (UGT) activities in hepatic microsomes from different species by UFLC-ESI-MS. J Pharm Biomed Anal 2011;54:236-41
124. Court MH, Greenblatt DJ. Molecular genetic basis for deficient acetaminophen glucuronidation by cats: UGT1A6 is a pseudogene, and evidence for reduced diversity of expressed hepatic UGT1A isoforms. Pharmacogenetics 2000;10:355-69 (Pubitemid 30345183)
125. Trepanier LA, Ray K, Winand NJ, et al. Cytosolic Arylamine N-acetyltransferase (NAT) deficiency in the dog and other canids due to an absence of NAT genes. Biochem Pharmacol 1997;54:73-80 (Pubitemid 27353223)
126. Punt A, Delatour T, Scholz G, et al. Tandem mass spectrometry analysis of N2-(trans-Isoestragole-3′-yl)-2′- deoxyguanosine as a strategy to study species differences in sulfotransferase conversion of the proximate carcinogen 1′-hydroxyestragole. Chem Res Toxicol 2007;20:991-8 (Pubitemid 47204812)
127. Huan JY, Miranda CL, Buhler DR, et al. Species differences in the hepatic microsomal enzyme metabolism of the pyrrolizidine alkaloids. Toxicol Lett 1998;99:127-37 (Pubitemid 29027796)
128. He YQ, Yang L, Liu HX, et al. Glucuronidation, a new metabolic pathway for pyrrolizidine alkaloids. Chem Res Toxicol 2010;23:591-9
129. Carlton BD, Aubrun JC, Simon GS. Effects of coumarin following perinatal and chronic exposure in Sprague-Dawley rats and CD-1 mice. Fundam Appl Toxicol 1996;30:145-51
130. Colalto C. Herbal interactions on absorption of drugs: mechanisms of action and clinical risk assessment. Pharmacol Res 2010;62:207-27
131. Cass H. Herbs for the nervous system: ginkgo, kava, valerian, passionflower. Semin Integrat Med 2004;82-8
132. Strassburg CP, Kneip S, Topp J, et al. Polymorphic gene regulation and interindividual variation of UDP-glucuronosyltransferase activity in human small intestine. J Biol Chem 2000;275:36164-71
133. Giacomini KM, Huang SM, Tweedie DJ, et al. Membrane transporters in drug development. Nat Rev Drug Discov 2010;9:215-36
134. Nabekura T, Kamiyama S, Kitagawa S. Effects of dietary chemopreventive phytochemicals on P-glycoprotein function. Biochem Biophys Res Commun 2005;327:866-70 (Pubitemid 40092828)
135. Juan H, Terhaag B, Cong Z, et al. Unexpected effect of concomitantly administered curcumin on the pharmacokinetics of talinolol in healthy Chinese volunteers. Eur J Clin Pharmacol 2007;63:663-8 (Pubitemid 46911338)
136. Nabekura T, Yamaki T, Ueno K, et al. Inhibition of P-glycoprotein and multidrug resistance protein 1 by dietary phytochemicals. Cancer Chemother Pharmacol 2008;62:867-73
137. Brand W, Schutte ME, Williamson G, et al. Flavonoid-mediated inhibition of intestinal ABC transporters may affect the oral bioavailability of drugs, food-borne toxic compounds and bioactive ingredients. Biomed Pharmacother 2006;60:508-19 (Pubitemid 44635082)
138. Sousa T, Paterson R, Moore V, et al. The gastrointestinal microbiota as a site for the biotransformation of drugs. Int J Pharm 2008;363:1-25
139. Ingelman-Sundberg M. Pharmacogenetics of cytochrome P450 and its applications in drug therapy: the past, present, and future. Trends Pharmacol Sci 2004;25:193-200 (Pubitemid 38519910)
140. Esser C, Jux B. Small chemicals, bioactivation, and the immune system-a fragile balance of i-Tox and benefits? Chem Biodivers 2009;6:2138-43